Disease/Infection News

RSS

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel antioxidant molecules targeting mitochondria, today announced that it has achieved significant positive results in its U.S. Phase II clinical trial of SkQ1 compound in patients with moderate to severe dry eye syndrome.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

24 Apr 2015

Twins pilot study shows genes may make some people more attractive to mosquitoes

The likelihood of being bitten by mosquitoes could be down to our genes, according to a study carried out on twins. Research from the London School of Hygiene & Tropical Medicine found, for the first time, an underlying genetic component to how attractive we are to mosquitoes and this is likely to be caused by genetic control of our body odour.

24 Apr 2015

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year.

23 Apr 2015

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

23 Apr 2015

Study highlights need to increase current levels of interventions to reduce HBV transmission

Results revealed today at The International Liver Congress 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.

23 Apr 2015

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Many countries in the World Health Organization European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver Congress 2015 has shown the devastating impact the infection has on their daily lives.

23 Apr 2015

Novel immunotherapeutic shows promise against chronic hepatitis B

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Civacir can effectively prevent HCV recurrence following liver transplants

New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).

23 Apr 2015

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan N.V. today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep in India.

23 Apr 2015

Study reveals impact of delaying HCV treatment

Data revealed today at The International Liver Congress 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients.

23 Apr 2015

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis.

23 Apr 2015

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Diseases and available online. The trends raise serious concerns about the effects on patient care, particularly for infections without effective alternative treatment options.

23 Apr 2015

New UM SOM study uncovers never-before-seen illness transmitted by ticks

Tick-borne diseases are a major public health problem around the world. Ticks carry and transmit a variety of microbes that cause disease. These illnesses, which include Lyme disease, Rocky Mountain spotted fever, and Tularemia, can cause a variety of symptoms, often serious and sometimes deadly.

23 Apr 2015

New patent-pending detection method identifies bacteria contaminating oysters

In a major breakthrough in shellfish management and disease prevention, researchers at the University of New Hampshire have discovered a new method to detect a bacterium that has contaminated New England oyster beds and sickened consumers who ate the contaminated shellfish.

23 Apr 2015

Adseverin protein plays key role in bone loss associated with osteoinflammatory disease

Adseverin, a protein found in the body, has been identified as the key driver behind the bone loss associated with the world's most common inflammatory disease: gum disease, or periodontitis.

23 Apr 2015

Disease/Infection News

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Twins pilot study shows genes may make some people more attractive to mosquitoes

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Study highlights need to increase current levels of interventions to reduce HBV transmission

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

Novel immunotherapeutic shows promise against chronic hepatitis B

Civacir can effectively prevent HCV recurrence following liver transplants

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Study reveals impact of delaying HCV treatment

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Rising shortages of key antibiotics raise serious concerns about effects on patient care

New UM SOM study uncovers never-before-seen illness transmitted by ticks

New patent-pending detection method identifies bacteria contaminating oysters

Adseverin protein plays key role in bone loss associated with osteoinflammatory disease

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News